



(43) International Publication Date
25 September 2014 (25.09.2014)

(10) International Publication Number
WO 2014/147044 A1

(51) International Patent Classification:
A61K 39/095 (2006.01)

(21) International Application Number:
PCT/EP2014/055355

(22) International Filing Date:
17 March 2014 (17.03.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/802,918 18 March 2013 (18.03.2013) US
61/874,008 5 September 2013 (05.09.2013) US

(71) Applicant: **GLAXOSMITHKLINE BIOLOGICALS S.A.** [BE/BE]; rue de l'Institut 89, B-1330 Rixensart (BE).

(72) Inventors: **BAINE, Yaela**; GlaxoSmithKline, 2301 Renaissance Boulevard, King of Prussia, Pennsylvania 19406 (US). **MILLER, Jacqueline**; GlaxoSmithKline, 2301 Renaissance Boulevard, King of Prussia, Pennsylvania 19406 (US).

(74) Agent: **JOHNSTON, Caroline Louise**; GlaxoSmithKline, Global Patents CN925.1, 980 Great West Road, Brentford Middlesex, TW8 9GS (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*

(54) Title: METHOD OF TREATMENT

(57) Abstract: The application discloses method of immunising against *Neisseria meningitidis* infection comprising the steps of a) immunising a human patient at a first age of between 0 and 1 months with a bacterial saccharide conjugate vaccine comprising at least one, two or three bacterial saccharide(s) separately conjugated to a carrier protein to form at least one, two or three bacterial saccharide conjugate(s); and b) immunising the human patient at a second age of between 12 and 24 months with a *Neisseria meningitidis* conjugate vaccine comprising at least two capsular saccharides selected from the group consisting of N. meningitidis serogroup A capsular saccharide (Men A), N. meningitidis serogroup C capsular saccharide (MenC), N. meningitidis serogroup W135 capsular saccharide (MenW135), and N. meningitidis serogroup Y capsular saccharide (MenY) conjugated separately to a carrier protein, wherein the *Neisseria meningitidis* conjugate vaccine is co-administered with a vaccine comprising diphtheria toxoid and tetanus toxoid.



WO 2014/147044 A1